NeuroDerm Announces Additions to Management Team
REHOVOT, Israel, July 06, 2016 -- (Healthcare Sales & Marketing Network) -- NeuroDerm Ltd. (NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the appointments of Tami Yardeni as Chie... Biopharmaceuticals, Devices, Neurology, PersonnelNeuroDerm, ND0612H, Parkinsons disease, Levodopa, Carbidopa (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 6, 2016 Category: Pharmaceuticals Source Type: news
Continuous L-Dopa Enteric Infusion Relieves RLS SymptomsContinuous L-Dopa Enteric Infusion Relieves RLS Symptoms
Continuous enteric infusion of levodopa markedly relieved symptoms of restless legs syndrome and improved quality of life in a patient with contraindications to alternative drugs, a case report shows. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 24, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Parkinson’s disease impairs masticatory function
ConclusionPD patients have impaired masticatory function during levodopa “on” periods compared to controls. Clinical relevanceKnowledge that PD is associated with impaired masticatory function is important to dental professionals in decision making related to prosthetics and general dental treatment. (Source: Dental Technology Blog)
Source: Dental Technology Blog - June 17, 2016 Category: Dentistry Source Type: news
Parkinson ’s disease impairs masticatory function
Conclusion < /h3 > < div class= " Para " id= " Par4 " > PD patients have impaired masticatory function during levodopa “on” periods compared to controls. < /div > < /div > < div class= " AbstractSection " id= " ASec5 " > < h3 class= " Heading " > Clinical relevance < /h3 > < div class= " Para " id= " Par5 " > Knowledge that PD is associated with impaired masticatory function is important to dental professionals in decision making related to prosthetics and general dental treatment. < /div > < /div > < /section > < h1 class= " ArticleTitle " lang= " en " > < /h1 > < /div > < div class= " panel " id= " abstract-a...
Source: Dental Technology Blog - June 17, 2016 Category: Dentistry Source Type: news
Extended-Release Amantadine May Improve Levodopa Dyskinesia Control
VANCOUVER — An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals. (Source: Caring for the Ages)
Source: Caring for the Ages - May 28, 2016 Category: Health Management Authors: M. Alexander Otto Source Type: news
Zambon Launches Xadago(R) (Safinamide) in the U.K. for Patients with Mid- to Late-Stage Parkinsons Disease
Zambon today announces the availability in the U.K. of Xadago® (safinamide) for the treatment of adult patients with idiopathic Parkinsons disease (PD) as an add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other Parki... Biopharmaceuticals, Neurology, Product LaunchNewron Pharmaceuticals, Zambon, Xadago, Parkinsons disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 23, 2016 Category: Pharmaceuticals Source Type: news
Parcopa (Carbidopa and Levodopa Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 13, 2016 Category: Drugs & Pharmacology Source Type: news
Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals.
Amantadine... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 21, 2016 Category: Neurology Source Type: news
Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals.
Amantadine... (Source: Family Practice News)
Source: Family Practice News - April 21, 2016 Category: Primary Care Source Type: news
Intec Pharma enrols first patient in phase III trial of AP-CDLD for advanced Parkinson's
Intec Pharma has enrolled the first patient in the US under its phase III clinical trial for Accordion Pill Carbidopa/Levodopa (AP-CDLD) for treatment of patients with advanced Parkinson's disease. (Source: Drug Development Technology)
Source: Drug Development Technology - April 4, 2016 Category: Pharmaceuticals Source Type: news
FDA Drug Safety Communication: Ongoing Safety Review of Stalevo and possible increased cardiovascular risk
[08-20-2010] The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data that suggest patients taking Stalevo (a combination of carbidopa/levodopa and entacapone) may be at an increased risk for cardiovascular events (heart attack, stroke, and cardiovascular death) compared to those taking carbidopa/levodopa (sold as the combination product, Sinemet). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 2, 2016 Category: Drugs & Pharmacology Source Type: news
FDA grants orphan status for Amarantus' eltoprazine to treat PD-LID
The US Food and Drug Administration (FDA) has granted orphan drug designation for Amarantus BioScience Holdings' (AMBS') eltoprazine to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 11, 2016 Category: Pharmaceuticals Source Type: news
Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
SAN FRANCISCO, February 10, 2016 -- (Healthcare Sales & Marketing Network) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that... Biopharmaceuticals, Neurology, FDAAmarantus BioScience, Eltoprazine, dyskinesia, Parkinson's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 10, 2016 Category: Pharmaceuticals Source Type: news
Medtech approvals: FDA releases November 2015 PMAs
The FDA today released its list of the pre-market approvals it granted for medical devices in November 2015:
Summary of PMA Originals & Supplements Approved
Originals: 3
Supplements: 69
Summary of PMA Originals Under Review
Total Under Review: 57
Total Active: 30
Total On Hold: 27
Summary of PMA Supplements Under Review
Total Under Review: 583
Total Active: 433
Total On Hold: 150
Summary of All PMA Submissions
Originals: 4
Supplements: 75
Summary of PMA Supplement PMA Approval/Denial Decision Times
Number of Approvals: 69
Number of Denials: 0
Average Days Fr Receipt to Decision (Total Time): 193.4
FDA Time: 1...
Source: Mass Device - January 22, 2016 Category: Medical Equipment Authors: MassDevice Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news
Dipraglurant receives orphan drug designation from the FDA for levodopa-induced dyskinesia associated with Parkinson's disease
Addex Therapeutics, a leading company pioneering allosteric modulation-based drug discovery and development, announced today that the US Food and Drug Administration (FDA) has granted orphan drug... (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - January 4, 2016 Category: Neurology Tags: Parkinson's Disease Source Type: news
